Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. 51st Annual Meeting and Exposition of the American-Society-of-Hematology Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., Horning, S. J. AMER SOC HEMATOLOGY. 2009: 663–63
View details for Web of Science ID 000272725802029